TrialNature medicine2021

Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial.

Thomas Bachelot et al.PubMed ↗Publisher ↗

No numbers read from the abstract.